Abstract
Objectives: The expression pattern of PAX5 in thetissue of superficial bladder transitional cell carcinoma (TCC), itsprognostic value and its correlation with p53immunohistochemistry and p53 mutation analysis were evaluated.Methods: Study comprised 61 patients with histologicallyconfirmed superficial bladder TCC. Expression level of PAX5mRNA was investigated using reverse transcriptase-polymerase chainreaction (RT-PCR) and determined semiquantitatively. The presence ofp53 mutations was determined by SSCP and confirmed by directsequencing. The p53 immunohistochemistry was performed with DO1antibody and semiquantitatively evaluated using HSCORE (HS) method. Asthe control group for the evaluation of the PAX5 expressionserved 8 men with benign prostatic hyperplasia. Results: PAX5 expression was found in 50 patients with bladder TCC butin no patient from the control group. Its quantity however correlatedneither with the stage nor with the grade of the tumor. P53mutation was confirmed only in 1 patient with pTaG2 tumor in exon 5(deletion of proline 128). On the contrary, positive immunohistochemicalstaining of p53 was detected in most patients. Using the cutoffvalue of HS 200, 56.9% of patients showed p53overexpression. Quantity of p53 immunochistochemical positivitydid not correlate with the quantity of PAX5 expression. Usingthe cutoff values of HS 200 for p53 and of 0.2 forPAX5, 7 of 8 patients with future progression had p53and 4 had PAX5 overexpression respectively.Conclusion: The expression of gene PAX5 is a frequentevent in superficial TCC of the bladder.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdel-Fattah R, Challen C, Griffiths TRL et al. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: High frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 1998; 77: 2230–2238.
Adshead JM, Ogden CW, Penny MA et al. The expression of PAX5 in human transitional cell carcinoma of the bladder: Relationship with de-differentiation. British J Urol International 1999; 83: 1039–1044.
Bártek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5: 893–899.
Berggren P, Steineck G, Adolfsson J et al. p53 mutations in urinary bladder cancer. Br J Cancer 2001; 84: 1505–1511.
Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletions of a tumor suppressor gene on chromosome 9. Oncogene 1993; 8: 1083–1085.
Cordon-Cardo C, Dalbagni G, Saez GT et al. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994; 56: 347–353.
Esrig D, Spruck ChH, Nichols PW et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 1389–1397.
Gardiner RA, Walsh MD, Allen V et al. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Br J Urol 1993; 73: 526–532.
Gontero P, Casetta G, Zitella A et al. Evaluation of p53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000; 38: 287–296.
Grompe M (1993). The rapid detection of unknown mutations in nucleic acids. Nat Genet 1993; 5: 111–117.
Heney NM, Ahmed S, Flanaghan MJ et al. Superficial bladder cancer: Progression and recurrence. J Urol 1983; 130: 1083–1086.
Kozmik Z, Sure U, Rüedi D et al. Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci 1995; 92: 5709–5713.
Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19: 573–580.
Levine AJ. p53, the cellular gatekeeper for growth and dividion. Cell 1997; 88: 323–331.
Llopis J, Alcaraz A, Ribal MJ et al. p53 expression predicts progression and poor survival in T1 bladder tumours. Eur Urol 2000; 37: 644–653.
Maulbecker CC, Gruss P. The oncogenic potential of Pax genes. EMBO J 1993; 12: 2361–2397.
Mc Carty KS Jr, Miller LS, Cox EB et al. Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716–721.
Nutt SL, Thevenin C, Busslinger M. Essential functions of Pax-5 (BSAP) in pro-B cell development. Immunobiol 1997; 198: 227–235.
Orlow I, Lianes P, Lacombe L et al. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res 1994; 54: 2848–2851.
Reiher F, Ozer O, Pins M et al. p53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol 2002; 167: 1469–1474.
Sarkis AS, Dalbagni G, Cordon-Cardo C et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 1993; 85: 53–59.
Schmitz-Dräger BJ, Goebell PJ, Ebert T, Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000; 38: 691–700.
Sedláček Z, Kodet R, Kříž V et al. Two Li-Fraumeni syndrome families with novel germline p53 mutations: Loss of the wild type allele in only 50% of tumours. Brit. J. Cancer 1998; 77: 1034–1039.
Serth J, Kuczyk MA, Bokmeyer C et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995; 71: 201–205.
Shigyo M, Sugano K, Fukayama N et al. Allelic loss on chromosome 9 in bladder cancer tissues and urine samples detected by blunt-end single-strand DNA conformation polymorphism. Int J Cancer 1998; 78: 425–429.
Sobin LH, Wittekind C. UICC TNM classification of malignant tumours, 5th ed. New York: Wiley Liss, 1997: 187–190.
Spruck CH, Ohneseit P, Gonzalez-Zulueta M et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784–788.
Stuart ET, Haffner R, Oren M, Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. The EMBO Journal 1995; 14: 5638–5645.
Stuart ET, Kioussi Ch, Aguzzi A, Gruss P. PAX5 expression correlates with increasing malignancy in human astrocytomas. Clinical Cancer Res 1995; 1: 207–214.
Urbánek P, Wang Z-Q, Fetka I et al. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/ BSAP. Cell 1994; 79: 901–912.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Babjuk, M., Soukup, V., Mareš, J. et al. The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome. Int Urol Nephrol 34, 495–501 (2002). https://doi.org/10.1023/A:1025652203472
Issue Date:
DOI: https://doi.org/10.1023/A:1025652203472